uniQure N.V.

NASDAQ:QURE

Biotechnology

Healthcare
$20.30 -2.34%

-$1.13 today

Market cap
$1.42B
Beta
1.00
P/E (TTM)
-14.1
EPS (TTM)
-$3.33
52W Low $8.73High $71.50

Volume 1.13M

Average 1.75M

QURE Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

uniQure N.V.NASDAQ: QURE

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns positive

Q1 FY2026 accounts receivables was $3.78M, compared with -$2.98M a year earlier. Trailing-twelve-month accounts receivables was -$1.84M. Over 3 fiscal years it compounded at -44.0% a year.

Context

  • Accounts receivables amounted to 53.4% of revenue in FY2025, up 45.1 pp from a year earlier.
  • Accounts receivables grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly accounts receivables holds near $3.78M or moves back toward the trailing-twelve-month quarterly average of -$459.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.78M+132.9% QoQ
Last fiscal yearDec 2025
-$8.6M+283.3% YoY
LTMMar 2026
-$1.84M-135.4% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+226.9%——
1 year+283.3%——
3-year CAGR-44.0%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(8.6M) USD
Year-over-year change
-283.3%

Accounts Receivables vs competitors

How QURE compares with its peers on the latest reported figures

  • QURE's LTM Mar 2026 accounts receivables of $1.84M is the 4th largest of the 8 companies compared; the peer median is $0.
  • Its year-over-year change of -135.4% is the 3rd highest of 5, against a peer median of -122.1%.
  • Accounts receivables amounts to 10.2% of revenue for QURE, versus a peer median of 3.3%.
QURE Competitors Peer median
Accounts Receivables for QURE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$22.06M -1708.0%+37.0%3.3%
MGTXMeiraGTx Holdings plcLTM Mar 2026$13.03M -178.8%—16.3%
RGNXREGENXBIO Inc.LTM Mar 2026$9.02M +328.9%—10.3%
QUREuniQure N.V.LTM Mar 2026$1.84M -135.4%-44.0%10.2%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$465K -65.5%-17.4%1.3%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
NGNENeurogene Inc.LTM Mar 2026$0 ———
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$0 ———
Peer median (excluding QURE) $0-122.1%+9.8%3.3%

Competitors are the stored peer set for QURE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income329.59M(126.79M)(308.48M)(239.56M)(198.97M)
Depreciation & Amortization7.3M8.54M11.9M12.64M14.76M
Deferred Income Tax3.21M(1.47M)1.92M2.43M1.59M
Stock-Based Compensation25.64M34.2M35.09M22.26M17.68M
Change in Working Capital(50.48M)(43.38M)81.12M(3.94M)(6.79M)
Accounts Receivables(58.96M)(49.08M)(1.32M)(2.24M)(8.6M)
Inventory0(6.92M)(6.74M)2.42M0
Accounts Payables(727K)9.24M(4.17M)1.52M(2.67M)
Other Working Capital9.2M3.39M93.36M(5.64M)4.47M
Other Non-Cash Items(27.29M)(16.16M)32.51M23.44M(6.23M)
Operating Cash Flow287.96M(145.06M)(145.93M)(182.73M)(177.96M)
Capital Expenditures(17.44M)(17.69M)(7.15M)(3.37M)(439K)
Acquisitions (Net)(49.95M)(1.9M)000
Purchases of Investments0(163.15M)(366.44M)(359.84M)(658.37M)
Sales of Investments00167.91M534.5M337.2M
Other Investing Activities00000
Investing Cash Flow(67.39M)(182.73M)(205.69M)162.97M(321.62M)
Debt Repayment62.5M0370.06M(53.05M)0
Common Stock Issued33.7M1.45M308K2.12M391.9M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.33M)0(7.65M)(8.56M)23.5M
Financing Cash Flow94.86M1.45M362.72M(59.49M)415.4M
Effect of Forex Changes(3.76M)(1.83M)2.27M(4.97M)5.49M
Net Change in Cash311.67M(328.18M)13.37M(84.22M)(78.69M)
Free Cash Flow270.52M(162.75M)(153.08M)(186.1M)(177.96M)

uniQure N.V.

NASDAQ:QURE

Intrinsic Alpha fair value

Locked

Current Price

$20.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.